Bank of New York Mellon Corp Has $35.45 Million Stake in Qiagen N.V. (NYSE:QGEN)

Bank of New York Mellon Corp trimmed its position in shares of Qiagen N.V. (NYSE:QGEN - Free Report) by 4.5% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 882,919 shares of the company's stock after selling 41,846 shares during the period. Bank of New York Mellon Corp owned 0.40% of Qiagen worth $35,449,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in QGEN. Groupama Asset Managment boosted its holdings in shares of Qiagen by 8,074.0% during the 4th quarter. Groupama Asset Managment now owns 31,817,740 shares of the company's stock worth $1,416,844,000 after buying an additional 32,216,761 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in shares of Qiagen by 9.5% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 25,319,332 shares of the company's stock worth $1,127,470,000 after purchasing an additional 2,202,040 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Qiagen by 2.5% in the 4th quarter. Wellington Management Group LLP now owns 21,782,305 shares of the company's stock worth $970,534,000 after purchasing an additional 531,362 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Qiagen by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 8,879,089 shares of the company's stock worth $397,937,000 after purchasing an additional 77,119 shares during the last quarter. Finally, Norges Bank bought a new stake in Qiagen during the 4th quarter worth about $181,529,000. 70.00% of the stock is currently owned by institutional investors.

Qiagen Stock Performance

QGEN stock traded up $0.56 during midday trading on Wednesday, reaching $48.01. 372,257 shares of the company were exchanged, compared to its average volume of 1,214,020. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.37 and a quick ratio of 2.83. The business has a 50-day moving average price of $45.58 and a two-hundred day moving average price of $42.88. Qiagen N.V. has a one year low of $37.63 and a one year high of $49.30. The firm has a market capitalization of $10.67 billion, a price-to-earnings ratio of 120.20, a price-to-earnings-growth ratio of 2.45 and a beta of 0.68.

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.55 EPS for the quarter, topping analysts' consensus estimates of $0.50 by $0.05. Qiagen had a net margin of 4.68% and a return on equity of 14.61%. The firm had revenue of $483.46 million during the quarter, compared to analysts' expectations of $465.66 million. During the same period in the previous year, the business posted $0.44 earnings per share. The company's revenue for the quarter was up 5.2% compared to the same quarter last year. Equities research analysts forecast that Qiagen N.V. will post 2.26 EPS for the current year.

Qiagen Announces Dividend

The company also recently disclosed a dividend, which was paid on Thursday, July 10th. Investors of record on Thursday, July 3rd were given a dividend of $0.25 per share. The ex-dividend date of this dividend was Wednesday, July 2nd. This represents a yield of 0.52%. Qiagen's dividend payout ratio is 62.50%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on QGEN. Robert W. Baird increased their price objective on shares of Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a report on Monday, April 21st. Bank of America increased their price objective on shares of Qiagen from $50.00 to $53.00 and gave the stock a "buy" rating in a report on Thursday, June 26th. Redburn Atlantic lowered shares of Qiagen from a "buy" rating to a "neutral" rating in a report on Friday, April 4th. Wall Street Zen raised shares of Qiagen from a "buy" rating to a "strong-buy" rating in a report on Thursday, May 15th. Finally, Barclays began coverage on shares of Qiagen in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 target price on the stock. Seven analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $49.40.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.